NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Altimmune, Inc. ALT
16 fiscal years on record · USD · FY2025 reported · SEC filings only
Growth
USD 41,000.00
Revenue, FY2025 · full 16-year series below
Revenue $M
Net income $M
FY2025 · Revenue 0.0 · Net income -88.1
Compound annual growth
Revenue compounded at −65.3% a year over five years.
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
−214861 cents
lost on every revenue dollar
Operating margin
Net margin
FY2025 · Operating -230461.0% · Net -214861.0%
ROE
FY2025 · ROE -50.6%
Each USD of equity lost 51 cents this year.
The 16-year record
16 fiscal years
Every figure from documents filed with the SEC · USD
EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.
row low → row highnegative
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue $B | 0.0 | 0.0 | 0.0 | −0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | · | · | · | · | 0.0 | 0.0 |
| Operating income $B | −0.1 | −0.1 | −0.1 | −0.1 | −0.1 | −0.1 | −0.0 | −0.0 | −0.1 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 |
| EBITDA $B | −0.1 | −0.1 | −0.1 | −0.1 | −0.1 | −0.1 | −0.0 | −0.0 | −0.1 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 |
| Income tax $B | −0.0 | · | · | −0.0 | · | −0.0 | −0.0 | −0.0 | −0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | · | · |
| Net income $B | −0.1 | −0.1 | −0.1 | −0.1 | −0.1 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 |
| Free cash flow $B | −0.1 | · | −0.1 | −0.1 | −0.1 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | · | −0.0 | −0.0 |
| EPS, diluted $ | −1.00 | −1.34 | −1.66 | −1.81 | −2.35 | −1.91 | −1.60 | −15.16 | −118.91 | −1.66 | −0.05 | −0.17 | −0.23 | −0.10 | −0.08 | −1.08 |
| Dividend / sh $ | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
| Payout % | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
| ROE % | −50.6 | −59.9 | −46.6 | −44.1 | −45.7 | −36.1 | −43.7 | −89.3 | −129.7 | −29.4 | −11.2 | −77.7 | −123.3 | −35.7 | −27.1 | −285.4 |
| Shares out B | 0.11 | 0.07 | 0.07 | 0.05 | 0.04 | 0.04 | 0.02 | 0.01 | 0.00 | 0.01 | 0.06 | 0.06 | 0.05 | 0.05 | 0.05 | 0.05 |
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Provenance
Company facts, as filed
How we verify · 0 failures in 64 reconciliationsAUDITED
Reconciled in 16 of 19 fiscal years. 12 checks could not be computed.
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2010